ADS024:

An LPAR3-targeted

biotherapeutic

ADS024:

An LPAR3-targeted

biotherapeutic

ADS024:

An LPAR3-targeted

biotherapeutic

ADS024:

An LPAR3-targeted

biotherapeutic

ADS024 is a non engrafting, naturally occurring single strain live biotherapeutic product (SS-LBP).

It is an orally dosed, anti-inflammatory SS-LBP that produces a selective agonist of the G protein-coupled receptor (GPCR) Lysophosphatidic acid receptor 3 (LPAR3).

ADS024 is a non engrafting, naturally occurring single strain live biotherapeutic product (SS-LBP).

It is an orally dosed, anti-inflammatory SS-LBP that produces a selective agonist of the G protein-coupled receptor (GPCR) Lysophosphatidic acid receptor 3 (LPAR3).

THE TARGET, LYSOPHOSPHATIDIC ACID RECEPTOR 3 (LPAR3)

THE TARGET, LYSOPHOSPHATIDIC ACID RECEPTOR 3 (LPAR3)

THE TARGET, LYSOPHOSPHATIDIC ACID RECEPTOR 3 (LPAR3)

LPAR3 is a G-protein coupled receptor (GPCR) in the EDG family of receptors (S1PRs/LPARs) known to modulate inflammation.

LPAR3 is expressed in the brain and has genetic associations with biomarkers in Alzheimer’s Disease.

LPAR3 agonism is a novel disease-modifying approach to neurodegeneration.

LPAR3 is a G-protein coupled receptor (GPCR) in the EDG family of receptors (S1PRs/LPARs) known to modulate inflammation.

LPAR3 is expressed in the brain and has genetic associations with biomarkers in Alzheimer’s Disease.

LPAR3 agonism is a novel disease-modifying approach to neurodegeneration.

LPAR3 is a G-protein coupled receptor (GPCR) in the EDG family of receptors (S1PRs/LPARs) known to modulate inflammation.

LPAR3 is expressed in the brain and has genetic associations with biomarkers in Alzheimer’s Disease.

LPAR3 agonism is a novel disease-modifying approach to neurodegeneration.

POTENT AGONISM

ADS024 is cultured to produce a potent selective agonist of LPAR3.


The bacteria is then lyophilized to a powder form that can be dosed orally.

GI RELEASE

The LPAR3 agonist remains

stably associated with ADS024 until it is orally dosed.


Studies in mice show that > 99.9% of the bacteria do not survive transit through the stomach and small intestine, therefore the LPAR3 agonist is likely released in the upper GI tract.

BRAIN EFFICACY

ADS024 has shown efficacy

in an AD model and in multiple models of other neurodegenerative and neuroinflammatory diseases suggesting impact regardless of the cause of damage.


The preclinical dataset generated to date strongly supports moving into human testing in AD patients.

POTENT AGONISM

POTENT AGONISM

ADS024 is cultured to produce a potent selective agonist of LPAR3.


The bacteria is then lyophilized to a powder form that can be dosed orally.

ADS024 is cultured to produce a potent selective agonist of LPAR3.


The bacteria is then lyophilized to a powder form that can be dosed orally.

GI RELEASE

GI RELEASE

The LPAR3 agonist remains

stably associated with ADS024 until it is orally dosed.


Studies in mice show that > 99.9% of the bacteria do not survive transit through the stomach and small intestine, therefore the LPAR3 agonist is likely released in the upper GI tract.

The LPAR3 agonist remains

stably associated with ADS024 until it is orally dosed.


Studies in mice show that > 99.9% of the bacteria do not survive transit through the stomach and small intestine, therefore the LPAR3 agonist is likely released in the upper GI tract.

BRAIN EFFICACY

BRAIN EFFICACY

ADS024 has shown efficacy

in an AD model and in multiple models of other neurodegenerative and neuroinflammatory diseases suggesting impact regardless of the cause of damage.


The preclinical dataset generated to date strongly supports moving into human testing in AD patients.

ADS024 has shown efficacy

in an AD model and in multiple models of other neurodegenerative and neuroinflammatory diseases suggesting impact regardless of the cause of damage.


The preclinical dataset generated to date strongly supports moving into human testing in AD patients.

SELECT PUBLICATIONS

Acton S and Chesnel L.
LPAR3; a shared target for neurodegenerative diseases?
Neural Regeneration Research 20(12): p 3527-3528, December 2025. | DOI: 10.4103/NRR.NRR-D-24-01024

Acton S, O’Donnell MM, Periyasamy K, Dixit B, Eishingodrelo H, Hill C, Paul Ross R, Chesnel L
LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models.
Brain Behav Immun. 2024 Aug 13:S0889-1591(24)00547-6

Irwin S, Chipina Estrada A, Nelson B, Bullock A, Limketkai B, Ho W, Acton S, Chesnel L, Koon HW
ADS024, a single-strain live biotherapeutic product of Bacillus velezensis allevates dextran sulfate-medicated colitis in mice, protects human colonic epithelial cells against apoptosiss, and maintains epithelial barrier funchtion.
Front Microbiol. 2024 Jan10;14:1284083

SELECT PUBLICATIONS

Acton S and Chesnel L.
LPAR3; a shared target for neurodegenerative diseases?
Neural Regeneration Research 20(12): p 3527-3528, December 2025. | DOI: 10.4103/NRR.NRR-D-24-01024

Acton S, O’Donnell MM, Periyasamy K, Dixit B, Eishingodrelo H, Hill C, Paul Ross R, Chesnel L
LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models.
Brain Behav Immun. 2024 Aug 13:S0889-1591(24)00547-6

Irwin S, Chipina Estrada A, Nelson B, Bullock A, Limketkai B, Ho W, Acton S, Chesnel L, Koon HW
ADS024, a single-strain live biotherapeutic product of Bacillus velezensis allevates dextran sulfate-medicated colitis in mice, protects human colonic epithelial cells against apoptosiss, and maintains epithelial barrier funchtion.
Front Microbiol. 2024 Jan10;14:1284083

SELECT PUBLICATIONS

Acton S and Chesnel L.
LPAR3; a shared target for neurodegenerative diseases?
Neural Regeneration Research 20(12): p 3527-3528, December 2025. | DOI: 10.4103/NRR.NRR-D-24-01024

Acton S, O’Donnell MM, Periyasamy K, Dixit B, Eishingodrelo H, Hill C, Paul Ross R, Chesnel L
LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models.
Brain Behav Immun. 2024 Aug 13:S0889-1591(24)00547-6

Irwin S, Chipina Estrada A, Nelson B, Bullock A, Limketkai B, Ho W, Acton S, Chesnel L, Koon HW
ADS024, a single-strain live biotherapeutic product of Bacillus velezensis allevates dextran sulfate-medicated colitis in mice, protects human colonic epithelial cells against apoptosiss, and maintains epithelial barrier funchtion.
Front Microbiol. 2024 Jan10;14:1284083

Explore

Alzheimer's

ADS024

Resources

Adiso Therapeutics

Investment/Partnering

Explore

Alzheimer's

ADS024

Resources

Adiso Therapeutics

Investment/Partnering

Explore

Alzheimer's

ADS024

Resources

Adiso Therapeutics

Investment/Partnering